Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408823 | 0.98 | CYP4F2 (0.55) | CYP4F2CYP4A11NPSR1CYP2C19MAPT | |
| SCHEMBL15572190 | 0.94 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1CYP2C19MAPT | |
| SCHEMBL17031937 | 0.89 | CYP4F2 (0.48) | CYP4F2CYP4A11NPSR1MAPTDPP4 | |
| SCHEMBL25477600 | 0.83 | CYP4F2 (0.39) | CYP4F2CYP4A11NPSR1CYP2C19 | |
| SCHEMBL23135868 | 0.82 | MAPK1 (0.39) | CYP4F2CYP4A11CYP2C19MAPTMEN1 | |
| SCHEMBL16660833 | 0.81 | DGAT1 (0.46) | CYP4F2CYP4A11NPSR1CYP2C19 | |
| SCHEMBL19753 | 0.81 | CYP2C19 (0.54) | CYP4F2CYP4A11NPSR1CYP2C19CYP3A4 | |
| SCHEMBL17857 | 0.81 | CYP4F2 (0.55) | CYP4F2CYP4A11NPSR1CYP2C19MAPT | |
| SCHEMBL8270187 | 0.81 | CYP4F2 (0.59) | CYP4F2CYP4A11NPSR1CYP2C19MAPT | |
| SCHEMBL12204121 | 0.80 | CYP4F2 (0.50) | CYP4F2CYP4A11NPSR1CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283530-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND APPLICATION THEREOF | BEIJING LIHE TECH LTD (CN) | 2017-10-05 | — | — | US | claimed |
| US-20160272733-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND APPLICATION THEREOF | BEIJING LIHE TECHNOLOGY LTD. (CN) | 2016-09-22 | — | — | US | claimed |
| CN-109535155-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2022-07-12 | — | — | CN | disclosed |
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-15 | — | — | US | disclosed |
| US-20210087151-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | SYNGENTA CROP PROTECTION AG (CH) | 2021-03-25 | — | — | US | disclosed |
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20190169328-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | RENQIU LIHE TECH LTD (CN) | 2019-06-06 | — | — | US | disclosed |
| US-10208146-B2 | Catalyst component for olefin polymerization and application thereof | BEIJING LIHE TECHNOLOGY LTD. (CN) | 2019-02-19 | — | — | US | disclosed |
| EP-2768830-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-09 | — | — | US | disclosed |
| US-9994546-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-8940737-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2768830-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2014029723-A1 | NEW BICYCLICPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055895-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-1178969-B1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-6479531-B1 | Gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1178969-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000027823-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | CYP4F2 4646/4885CYP4A11 4549/4885NPSR1 4769/4885 |
| US-11274083-B2 | Substituted thiophenyl uracils, salts thereof and the use thereof as herbicidal agents | UNG, TYMP, TYMS | CYP4F2 115/4885CYP4A11 818/4885NPSR1 3414/4885 |
| US-20210087151-A1 | SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | UNG, TYMP, TYMS | CYP4F2 115/4885CYP4A11 818/4885NPSR1 3414/4885 |
| US-10208146-B2 | Catalyst component for olefin polymerization and application thereof | TEC, ETFA, TECR | CYP4F2 31/4885CYP4A11 171/4885NPSR1 4663/4885 |
| US-20190169328-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | COG2, GTF2I, POF1B | CYP4F2 148/4885CYP4A11 660/4885NPSR1 3683/4885 |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | CYP4F2 4646/4885CYP4A11 4549/4885NPSR1 4769/4885 |
| US-20170283530-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND APPLICATION THEREOF | TEC, ETFA, TECR | CYP4F2 31/4885CYP4A11 171/4885NPSR1 4663/4885 |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2A1, BCL2L1, BCL2L11 | CYP4F2 4543/4885CYP4A11 4568/4885NPSR1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.